Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Lung highlights from ESMO 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 2408

Dr Federico Cappuzzo - AUSL della Romagna-Ravenna, Ravenna, Italy

Dr Capuzzo speaks with ecancer at ESMO 2018 in Munich about results from lung cancer trials reported at the conference.

He reports a confirmed survival benefit in the PACIFIC trial for patients with high and medium PD-L1 expression, and negative results from a second-line study of atezolizumab in small cell lung cancer, as discussed by Dr Jean-Louis Pujol.

Dr Capuzzo also spoke with ecancer about the IMpower130 study of atezolizumab as first-line NSCLC therapy.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation